Benzimidazolone derived inhibitors of BCL6

Abstract

The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

Description

BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 INTRODUCTION

[0001] The present invention relates to certain compounds that function as inhibitors of BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated. BACKGROUND OF THE INVENTION

[0002] BCL6 is a zinc finger transcription repressor that plays a key role in the formation and development of germinal centres, in which B cells undergo somatic hypermutation and recombination of the immunoglobulin genes, in order to generate diversity in antibodies against a variety of foreign antigens (Dent et al., Science, 1997, 276, 589-592). BCL6 allows the proliferation of antibody producing B cells by repressing genes involved in DNA damage response, cell cycle arrest and apoptosis. BCL6 mediates this repression by recruiting the corepressor proteins SMRT, NCoR and BCoR to an extended groove motif that forms along the dimer interface of the BCL6 BTB (BR-C, Ttk and Bab) domain (Ahmad et al., Mol Cell, 2003, 12, 1551-1564; Ghetu et al., Mol Cell, 2008, 29, 384-391). Genetic upregulation of the BCL6 gene, as seen in many lymphomas, leads to malignant B cell proliferation (Hatzi & Melnick, Trends Mol Med, 2014, 20, 343-352). Therefore, there exists a need to develop agents that inhibit the tumourigenic effects of BCL6, either by selectively binding to the BTB domain and preventing corepressor recruitment, or by binding to the BTB domain and inducing protein degradation (Kerres et al. Cell Rep., 2017, 20, 2860-2875). SUMMARY OF THE INVENTION

[0003] According to a first aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0004] According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0005] According to a further aspect of the present invention, there is provided a method of inhibiting BCL6 activity, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein.

[0006] According to a further aspect of the present invention, there is provided a method of inhibiting cell proliferation, in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0007] According to a further aspect of the present invention, there is provided a method of treating a disease or disorder in which BCL6 activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0008] According to a further aspect of the present invention, there is provided a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0009] According to a further aspect of the present invention, there is provided a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0010] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in therapy.

[0011] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.

[0012] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of cancer. In a particular embodiment, the cancer is human cancer.

[0013] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the inhibition of BCL6 activity.

[0014] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the treatment of a disease or disorder in which BCL6 activity is implicated.

[0015] According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a proliferative condition.

[0016] Suitably, the proliferative disorder is cancer, suitably a human cancer (for example haematological cancers such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL) and angioimmunoblastic T-cell lymphoma (AITL)), leukaemias (including acute lymphoblastic leukaemia (ALL) and chronic myeloid leukaemia (CML)) and multiple myeloma, and solid tumours (including glioma, breast cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinomas (SCC) (including SCC of the head and neck, oesophagus, lung and ovary))).

[0017] According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer.

[0018] According to a further aspect of the present invention, there is provided a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of BCL6 activity.

[0019] According to a further aspect of the present invention, there is provided a use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a disease or disorder in which BCL6 activity is implicated.

[0020] According to a further aspect of the present invention, there is provided a process for preparing a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0021] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by, or obtained by, or directly obtained by a process of preparing a compound as defined herein.

[0022] According to a further aspect of the present invention, there are provided novel intermediates as defined herein which are suitable for use in any one of the synthetic methods set out herein.

[0023] Features, including optional, suitable, and preferred features in relation to one aspect of the invention may also be features, including optional, suitable and preferred features in relation to any other aspect of the invention. DETAILED DESCRIPTION OF THE INVENTION Definitions

[0024] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.

[0025] It is to be appreciated that references to "treating" or "treatment" include prophylaxis as well as the alleviation of established symptoms of a condition. "Treating" or "treatment" of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.

[0026] A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

[0027] In this specification the term "alkyl" includes both straight and branched chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched chain alkyl groups such as "isopropyl" are specific for the branched chain version only. For example, "(1-6C)alkyl" includes (1- 4C)alkyl, (1-3C)alkyl, propyl, isopropyl and t-butyl.

[0028] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms.

[0029] An "alkylene" group is an alkyl group that is positioned between and serves to connect two other chemical groups. Thus, "(1-6C)alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), 2-methylpropylene (-CH2CH(CH3)CH2-), pentylene (- CH2CH2CH2CH2-), and the like.

[0030] "(3-10C)cycloalkyl" means a hydrocarbon ring containing from 3 to 10 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and bicyclo[2.2.1]heptyl.

[0031] "(3-10C)cycloalkenyl" means a hydrocarbon ring containing from 3 to 10 carbon atoms and at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3-cyclohexen-1-yl, or cyclooctenyl.

[0032] The term "halo" or "halogeno" refers to fluoro, chloro, bromo and iodo, suitably fluoro, chloro and bromo, more suitably, fluoro and chloro.

[0033] The term "heterocyclyl", "heterocyclic" or "heterocycle" means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepine. Other heterocycles include dihydro-oxathiolyl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as tetrahydrothiene 1,1-dioxide and thiomorpholinyl 1,1-dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=O) or thioxo (=S) substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person would appreciate, any heterocycle may be linked to another group via any suitable atom, such as via a carbon or nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1- yl or morpholin-4-yl ring that is linked via the ring nitrogen.

[0034] By "bridged ring systems" is meant ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza- bicyclo[3.2.1]octane and quinuclidine.

[0035] By "spiro bi-cyclic ring systems" we mean that the two ring systems share one common spiro carbon atom, i.e. the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 6- azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptanes, 2-oxa-6- azaspiro[3.3]heptanes, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7- azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.

[0036] The term "heteroaryl" or "heteroaromatic" means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 1-4, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10- membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heteroaryl ring will contain up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

[0037] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Examples of partially aromatic heteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo- 1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro- benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7- tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.

[0038] Examples of five membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0039] Examples of six membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.

[0040] A bicyclic heteroaryl group may be, for example, a group selected from: a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms; and a cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms.

[0041] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl and pyrazolopyridinyl groups.

[0042] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolizinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl and pteridinyl groups.

[0043] The term "aryl" means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In a particular embodiment, an aryl is phenyl.

[0044] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. The term "wherein a / any CH, CH2, CH3 group or heteroatom (i.e. NH) within a R1 group is optionally substituted" suitably means that (any) one of the hydrogen radicals of the R¹ group is substituted by a relevant stipulated group.

[0045] Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

[0046] The phrase "compound of the invention" means those compounds which are disclosed herein, both generically and specifically. Compounds of the invention

[0047] In one aspect, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural formula (I), shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (I) wherein: X1 is selected from N or CRa wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, S, SO, SO2, <semantics>N(Re)<annotation encoding="application / x-tex">N(R^e)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Re)<annotation encoding="application / x-tex">C(O)N(R^e)< / annotation>< / semantics>, <semantics>N(Re)C(O)<annotation encoding="application / x-tex">N(R^e)C(O)< / annotation>< / semantics>, <semantics>N(Re)C(O)N(Rf)<annotation encoding="application / x-tex">N(R^e)C(O)N(R^f)< / annotation>< / semantics>, <semantics>N(Re)C(O)O<annotation encoding="application / x-tex">N(R^e)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Re)<annotation encoding="application / x-tex">OC(O)N(R^e)< / annotation>< / semantics>, <semantics>S(O)2N(Re)<annotation encoding="application / x-tex">S(O)_2N(R^e)< / annotation>< / semantics>, or N(Re)SO2, wherein Re and Rf are each independently selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(O)R9, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)yRg<annotation encoding="application / x-tex">S(O)_yR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein Rg, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or Rg and Rh can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy; R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)RI, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> N(Rn)SO2, wherein Rn is selected from hydrogen or (1- 2C)alkyl; 11 L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, <semantics>C(O)R∘<annotation encoding="application / x-tex">C(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)OR∘<annotation encoding="application / x-tex">C(O)OR^{\circ}< / annotation>< / semantics>, <semantics>OC(O)R∘<annotation encoding="application / x-tex">OC(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)N(Ro)Rp<annotation encoding="application / x-tex">C(O)N(R^{o})R^{p}< / annotation>< / semantics>, <semantics>NRoC(O)Rp<annotation encoding="application / x-tex">NR^{o}C(O)R^{p}< / annotation>< / semantics>, wherein <semantics>Ro<annotation encoding="application / x-tex">R^{o}< / annotation>< / semantics> and <semantics>Rp<annotation encoding="application / x-tex">R^{p}< / annotation>< / semantics> are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જ denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-4C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; and R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), C(O)N(<semantics>ℝs<annotation encoding="application / x-tex">\mathbb{R}^s< / annotation>< / semantics>), <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, S(O)2N(Rs), N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Lz is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and Wz is aryl, heteroaryl, 4- to 7-membered heterocyclyl, 3- to 6-membered carbocycyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, <semantics>COORxa<annotation encoding="application / x-tex">COOR^{xa}< / annotation>< / semantics>, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, heteroaryl, 4- to 7-membered heterocyclyl or 3- to 6-membered carbocycyl is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano or hydroxy; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: ליל denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, OC(O)N(Rw), S(O)2N(Rw), N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and Z₅ is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ליל denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy; Xh, Xi and Xi are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; with the proviso that: (i) when R3 is a group of Formula B, no more than two of Xc, Xd and Xe are nitrogen; (ii) when <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics> is a group of Formula C, no more than three of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are nitrogen; (iii) when X1 and X2 are CH, R1 and R2 are hydrogen or methyl, R3 is a group of Formula A, Xa is N, Xb is CH and R9 is methyl or fluoro, R10 is not a methylsulfonylaminophenyl or an aminosulfonylphenyl; (iv) when Y3 is NH, each of R1 and R2 are not hydrogen or methyl; and (v) the compound is not one of the following: [Image disponible dans le document PDF, Image available in the PDF document]

[0048] In an embodiment, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural formula (I), shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (I) wherein: X1 is selected from N or CRa wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, S, SO, SO2, N(Re), C(O), C(O)O, OC(O), C(O)N(Re), <semantics>N(Re)C(O)<annotation encoding="application / x-tex">N(R^e)C(O)< / annotation>< / semantics>, <semantics>N(Re)C(O)N(Rf)<annotation encoding="application / x-tex">N(R^e)C(O)N(R^f)< / annotation>< / semantics>, <semantics>N(Re)C(O)O<annotation encoding="application / x-tex">N(R^e)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Re)<annotation encoding="application / x-tex">OC(O)N(R^e)< / annotation>< / semantics>, <semantics>S(O)2N(Re)<annotation encoding="application / x-tex">S(O)_2N(R^e)< / annotation>< / semantics>, or N(Re)SO2, wherein Re and Rf are each independently selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NRgRh, ORg, C(O)Rg, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)yRg<annotation encoding="application / x-tex">S(O)_yR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein Rg, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or Rg and Rh can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy; R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Ri and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)RI, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, <semantics>C(O)R∘<annotation encoding="application / x-tex">C(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)OR∘<annotation encoding="application / x-tex">C(O)OR^{\circ}< / annotation>< / semantics>, <semantics>OC(O)R∘<annotation encoding="application / x-tex">OC(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)N(Ro)Rp<annotation encoding="application / x-tex">C(O)N(R^{o})R^{p}< / annotation>< / semantics>, <semantics>NRoC(O)Rp<annotation encoding="application / x-tex">NR^{o}C(O)R^{p}< / annotation>< / semantics>, wherein <semantics>Ro<annotation encoding="application / x-tex">R^{o}< / annotation>< / semantics> and <semantics>Rp<annotation encoding="application / x-tex">R^{p}< / annotation>< / semantics> are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; and R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ליל denotes the point of attachment; Xa and Xb are independently selected from N or CRx1 wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), C(O)N(<semantics>ℝs<annotation encoding="application / x-tex">\mathbb{R}^{s}< / annotation>< / semantics>), <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, S(O)2N(Rs), N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Lz is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1- 2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(O)Rxa, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જ denotes the point of attachment; Xc. Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, OC(O)N(Rw), S(O)2N(Rw), N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ליל denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy; Xh, Xi and Xj are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; with the proviso that: (i) when R3 is a group of Formula B, no more than two of Xc, Xd and Xe are nitrogen; and (ii) when <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics> is a group of Formula C, no more than three of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are nitrogen.

[0049] In another embodiment, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural formula (I), shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (I) wherein: X1 is selected from N or CRa wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen. hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2- 4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, S, SO, SO2, N(Re), C(O), C(O)O, OC(O), C(O)N(Re), <semantics>N(Re)C(O),N(Re)C(O)N(Rf),N(Re)C(O)O,OC(O)N(Re),S(O)2N(Re),or<annotation encoding="application / x-tex">N(R^{e})C(O), N(R^{e})C(O)N(R^{f}), N(R^{e})C(O)O, OC(O)N(R^{e}), S(O)_{2}N(R^{e}), or< / annotation>< / semantics> N(Re)SO2, wherein Re and Rf are each independently selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NRgRh, ORg, C(O)Rg, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)vRg<annotation encoding="application / x-tex">S(O)_vR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein R9, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or Rg and Rn can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy; R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Ri and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R' is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> N(Rn)SO2, wherein Rn is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, C(O)R°, C(O)OR°, OC(O)R°, <semantics>C(O)N(R∘)Rp<annotation encoding="application / x-tex">C(O)N(R^{\circ})R^{p}< / annotation>< / semantics>, <semantics>NR∘C(O)Rp<annotation encoding="application / x-tex">NR^{\circ}C(O)R^{p}< / annotation>< / semantics>, wherein <semantics>R∘<annotation encoding="application / x-tex">R^{\circ}< / annotation>< / semantics> and <semantics>Rp<annotation encoding="application / x-tex">R^{p}< / annotation>< / semantics> are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1- 2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; and R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, S(O)2N(Rs), N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rw)<annotation encoding="application / x-tex">OC(O)N(R^w)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)SO2<annotation encoding="application / x-tex">N(R^w)SO_2< / annotation>< / semantics>, wherein <semantics>Rw<annotation encoding="application / x-tex">R^w< / annotation>< / semantics> and <semantics>Rx<annotation encoding="application / x-tex">R^x< / annotation>< / semantics> are each independently selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xq are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; with the proviso that: (i) when R3 is a group of Formula B, only one or two of Xc, Xd and Xe are nitrogen; and (ii) when <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics> is a group of Formula C, no more than three of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> are nitrogen.

[0050] In a particular group of compounds of the present invention, when R3 is a group of Formula B, no more than one of <semantics>Xc<annotation encoding="application / x-tex">X_c< / annotation>< / semantics>, <semantics>Xd<annotation encoding="application / x-tex">X_d< / annotation>< / semantics> and <semantics>Xe<annotation encoding="application / x-tex">X_e< / annotation>< / semantics> is nitrogen.

[0051] In a particular group of compounds of the present invention, when R3 is a group of Formula C, no more than two of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are nitrogen.

[0052] In a particular group of compounds of the present invention, when R3 is a group of Formula C, no more than one of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> is nitrogen.

[0053] In a particular group of compounds of the present invention, when R1 is hydrogen, R2 is not hydrogen.

[0054] Particular compounds of the invention include, for example, compounds of the Formula I, or pharmaceutically acceptable salts, hydrates and / or solvates thereof, wherein, unless otherwise stated, each of X1, X2, R1, R2, R3 and any associated substituent groups has any of the meanings defined hereinbefore or in any of paragraphs (1) to (89) hereinafter:- (1) X₁ is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CHF2, CF3, OCF3, acetylenyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1- 2C)alkyl; (2) X₁ is selected from N or CR³, wherein R³ is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano or NH2; (3) X₁ is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, acetylenyl, cyano or NH2; (4) X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, acetylenyl or cyano; (5) X₁ is selected from N or CR³, wherein R³ is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH₃ or cyano; (6) X₁ is selected from N or CR³ wherein R³ is selected from hydrogen, methyl, fluoro or chloro; (7) X1 is selected from N or CH; (8) X1 is N; (9) X₁ is CH; (10) X2 is selected from N, CH, CF or C-CH3; (11) <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is selected from N or CH; (13) X2 is selected from CH, CF or C-CH3; (15) R1 is selected from hydrogen or a group of the formula: -L-Y-Z wherein: L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, S, SO, SO2, N(Re), C(O), C(O)O, OC(O), C(O)N(Re), <semantics>N(Re)C(O)<annotation encoding="application / x-tex">N(R^e)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Re)<annotation encoding="application / x-tex">S(O)_2N(R^e)< / annotation>< / semantics>, or <semantics>N(Re)SO2<annotation encoding="application / x-tex">N(R^e)SO_2< / annotation>< / semantics>, wherein <semantics>Re<annotation encoding="application / x-tex">R^e< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(O)R9, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)yRg<annotation encoding="application / x-tex">S(O)_yR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein Rg, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or Rg and Rh can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring which is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano or hydroxy; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl; Y is absent or O, S, SO, SO2, N(Re), C(O), C(O)O, OC(O), C(O)N(Re), <semantics>N(Re)C(O)<annotation encoding="application / x-tex">N(R^e)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Re)<annotation encoding="application / x-tex">S(O)_2N(R^e)< / annotation>< / semantics>, or <semantics>N(Re)SO2<annotation encoding="application / x-tex">N(R^e)SO_2< / annotation>< / semantics>, wherein <semantics>Re<annotation encoding="application / x-tex">R^e< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(O)R9, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)yRg<annotation encoding="application / x-tex">S(O)_yR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein R9, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or Rg and Rh can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-9 membered heterocyclic ring; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene; Y is absent or O, <semantics>SO2<annotation encoding="application / x-tex">SO_2< / annotation>< / semantics>, <semantics>N(Re)<annotation encoding="application / x-tex">N(R^e)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Re)<annotation encoding="application / x-tex">C(O)N(R^e)< / annotation>< / semantics>, <semantics>N(Re)C(O)<annotation encoding="application / x-tex">N(R^e)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Re)<annotation encoding="application / x-tex">S(O)_2N(R^e)< / annotation>< / semantics>, or <semantics>N(Re)SO2<annotation encoding="application / x-tex">N(R^e)SO_2< / annotation>< / semantics>, wherein <semantics>Re<annotation encoding="application / x-tex">R^e< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(O)R9, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)vRg<annotation encoding="application / x-tex">S(O)_vR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein Rg, Rh and Ri are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; (18) R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene; Y is absent or O, SO2, C(O), C(O)O, C(O)N(Re) or S(O)2N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh, OR9, C(O)R9, <semantics>C(O)ORg<annotation encoding="application / x-tex">C(O)OR^g< / annotation>< / semantics>, <semantics>OC(O)Rg<annotation encoding="application / x-tex">OC(O)R^g< / annotation>< / semantics>, <semantics>C(O)N(Rg)Rh<annotation encoding="application / x-tex">C(O)N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)C(O)Rh<annotation encoding="application / x-tex">N(R^g)C(O)R^h< / annotation>< / semantics>, <semantics>S(O)yRg<annotation encoding="application / x-tex">S(O)_yR^g< / annotation>< / semantics> (where y is 0, 1 or 2), <semantics>SO2N(Rg)Rh<annotation encoding="application / x-tex">SO_2N(R^g)R^h< / annotation>< / semantics>, <semantics>N(Rg)SO2Rg<annotation encoding="application / x-tex">N(R^g)SO_2R^g< / annotation>< / semantics>, <semantics>Si(Rg)(Rh)Ri<annotation encoding="application / x-tex">Si(R^g)(R^h)R^i< / annotation>< / semantics> or <semantics>(CH2)zNRgRh<annotation encoding="application / x-tex">(CH_2)_zNR^gR^h< / annotation>< / semantics> (where z is 1, 2 or 3); wherein Rg, Rh and Ri are each independently selected from hydrogen or (1-4C)alkyl; (19) R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene; Y is absent or O, SO₂, C(O), C(O)O, C(O)N(Re) or S(O)₂N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulphamoyl, mercapto, ureido, NR9Rh or OR9; wherein R9, Rh and R' are each independently selected from hydrogen or (1- 4C)alkyl; (20) R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-5C)alkylene; Y is absent or O, SO2, C(O), C(O)O, C(O)N(Re) or S(O)2N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3- 10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NRgRh or OR9; wherein R9, Rh and Ri are each independently selected from hydrogen or (1-4C)alkyl; (21) R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-3C)alkylene; Y is absent or O, C(O), C(O)O or C(O)N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, (3- 6C)cycloalkyl, (3-6C)cycloalkenyl, a 5 or 6 membered heteroaryl or a 4- to 7-membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1- 2C)aminoalkyl, cyano, hydroxy, NR9Rh or OR9; wherein R9, Rh and Ri are each independently selected from hydrogen or (1-4C)alkyl; (22) R1 is selected from hydrogen or a group of the formula: -L-Y-Z wherein: L is absent or (1-3C)alkylene; Y is absent or O, C(O), C(O)O or C(O)N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, (3- 6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1- 2C)aminoalkyl, cyano, hydroxy, NR9Rh or OR9; wherein R9, Rh and Ri are each independently selected from hydrogen or (1-4C)alkyl; (23) R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-3C)alkylene; Y is absent or O, C(O), C(O)O or C(O)N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 4- to 7-membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or NH2; R1 is selected from hydrogen or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-3C)alkylene; Y is absent or O, C(O), C(O)O or C(O)N(Re), wherein Re is selected from hydrogen or (1-4C)alkyl; and Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or NH2; (25) R1 is selected from hydrogen or a group of the formula: -L-Z wherein: L is absent or (1-3C)alkylene; and Z is (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6 membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NRgRh or OR9; wherein R9 and Rh are each independently selected from hydrogen or (1-2C)alkyl; (26) R1 is selected from hydrogen or a group of the formula: -L-Z wherein: L is absent or (1-2C)alkylene; and Z is (1-6C)alkyl, (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NR9Rh or OR9; wherein R9 and Rh are each independently selected from hydrogen or (1-2C)alkyl; <semantics>(27)<annotation encoding="application / x-tex">(27)< / annotation>< / semantics> R1 is selected from hydrogen, (1-6C)alkyl or a group of the formula: -L-Z wherein: L is (1-2C)alkylene; and Z is (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NRgRh or OR9; wherein R9 and Rh are each independently selected from hydrogen or methyl; (28) R1 is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; wherein each (1- 6C)alkyl or (3-6C)cycloalkyl is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or NH2; (29) R1 is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; (30) R1 is selected from hydrogen or (1-4C)alkyl (e.g. methyl); (31) R1 is (1-4C)alkyl (e.g. methyl); (32) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Ri and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)RI, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein R' and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn)<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-4C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (33) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CR4R5 or C(O), wherein R4 and R5 are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)R1, SO2R1, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn)<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (34) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)RI, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, <semantics>N(Rn)<annotation encoding="application / x-tex">N(R^n)< / annotation>< / semantics>, C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or methyl; R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)RI, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1- 2C)alkyl or halo; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from (1-2C)alkyl, fluoro, chloro, hydroxy, (1- 2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, wherein Rac and Rad are independently selected from hydrogen or methyl; (36) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)alkoxy, amino, cyano or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from (1-2C)alkyl, fluoro, chloro, hydroxy, (1- 2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, wherein Rac and Rad are independently selected from hydrogen or methyl; R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> N(Rn)SO2, wherein Rn is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2- 4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, C(O)R°, C(O)OR°, OC(O)R°, <semantics>C(O)N(Ro)Rp<annotation encoding="application / x-tex">C(O)N(R^{o})R^{p}< / annotation>< / semantics>, <semantics>NRoC(O)Rp<annotation encoding="application / x-tex">NR^{o}C(O)R^{p}< / annotation>< / semantics>, wherein <semantics>Ro<annotation encoding="application / x-tex">R^{o}< / annotation>< / semantics> and <semantics>Rp<annotation encoding="application / x-tex">R^{p}< / annotation>< / semantics> are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1- 2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1- 2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (38) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rn)<annotation encoding="application / x-tex">S(O)_2N(R^n)< / annotation>< / semantics>, or <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1- 4C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1- 2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (39) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH₂F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rn)<annotation encoding="application / x-tex">S(O)_2N(R^n)< / annotation>< / semantics>, or <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1- 2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5- membered heteroaryl, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (40) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1- 2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ાર્જ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (41) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6- membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; R100 is selected from hydrogen, (1-2C)alkyl, -C(O)-CH3 or -C(O)ORab, wherein Rab is (1-2C)alkyl; (42) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જુ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; R101 and R102 are each independently selected from hydrogen, (1- 2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (43) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H, CF3 or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H, CF3, (1-2C)alkoxy, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 4-6-membered carbocyclic ring or a 4-6-membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; R101 is selected from hydrogen or methyl; and R102 is selected from (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (44) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ાર્જ denotes the point of attachment; W1 is selected from CR4R5 or C(O), wherein R4 and R5 are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (45) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: 62 [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵ or C(O), wherein R⁴ and R⁵ are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, C(O), C(O)O, OC(O), <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (46) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1-2C)alkyl; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, N(Rn), SO2, C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics>, <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rn)<annotation encoding="application / x-tex">S(O)_2N(R^n)< / annotation>< / semantics>, or <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein Rn is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (47) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH₂F, CF2H, CF3 or amino; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), SO2, C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rn)<annotation encoding="application / x-tex">C(O)N(R^n)< / annotation>< / semantics> or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro, CH2F, CF2H or CF3, (1-2C)alkoxy, amino, cyano or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or-NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (48) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH₂F, CF2H, CF3 or amino; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F, CF2H or CF3; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, C(O)O, C(O)N(Rn) or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, fluoro, chloro or hydroxy; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, hydroxy, (1-2C)alkoxy or -C(O)ORac, and wherein Rac is selected from hydrogen or (1-2C)alkyl; (49) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: 69 [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH₂F, CF2H or amino; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, C(O)O, C(O)N(Rn) or <semantics>N(Rn)C(O)<annotation encoding="application / x-tex">N(R^n)C(O)< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6- membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 is selected from hydrogen or methyl and R102 is selected from (1-2C)alkyl, hydroxy, (1-2C)alkoxy, C(O)ORac or -NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl; (50) R2 is selected from: (i) hydrogen or methyl; (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano or (1-2C)alkoxy; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: 71 R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, C(O)O, C(O)N(Rn) or N(Rn)C(O), wherein Rn is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3- 6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or pyrazolyl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or (iii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab wherein Rab is (1-2C)alkyl, R101 is selected from hydrogen or methyl and R102 is selected from (1-2C)alkyl, hydroxy or C(O)ORac wherein Rac is selected from hydrogen or (1- 2C)alkyl; (51) R2 is selected from a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4, wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano or (1-2C)alkoxy; W2 is CR6R7R8, wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or pyrazolyl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; (52) R2 is selected from a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W2 is CR6R7R8, wherein: R6 is selected from (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; and R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy; (53) R2 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: পৈ denotes the point of attachment; (54) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics> or <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein Rs is selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics> COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or 6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics> or N(Rw)SO2, wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z₅ is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics> are independently selected from N or <semantics>CR13<annotation encoding="application / x-tex">CR^{13}< / annotation>< / semantics>, wherein R13 is selected from hydrogen, fluoro, chloro, (1- 2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; (55) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ર્જ denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x_1}< / annotation>< / semantics> wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics> or <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein Rs is selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-3C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and WZ is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and <semantics>𝖱𝗑𝖻<annotation encoding="application / x-tex">\mathsf{R}^\mathsf{xb}< / annotation>< / semantics> are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: পুর্ব denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics> or N(Rw)SO2, wherein Rw is selected from hydrogen or (1-4C)alkyl; and <semantics>Z5<annotation encoding="application / x-tex">Z_5< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics> are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1- 2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; (56) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics> or <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein Rs is selected from hydrogen or (1- 4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Lz is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- <semantics>4C<annotation encoding="application / x-tex">4C< / annotation>< / semantics>)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics> or N(Rw)SO2, wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z₅ is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics> are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1- 2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; (57) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x_1}< / annotation>< / semantics> wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O), S(O)2N(Rs) or N(Rs)SO2, wherein Rs is selected from hydrogen or (1-4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: LZ is absent or a (1-3C)alkylene; and Wz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(O)Rxa, COORxa, C(O)NRxaRxb or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein <semantics>Rxa<annotation encoding="application / x-tex">R^{xa}< / annotation>< / semantics> and <semantics>Rxb<annotation encoding="application / x-tex">R^{xb}< / annotation>< / semantics> are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ליל denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, methyl, CH2F, CF2H or CF3; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; (58) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x_1}< / annotation>< / semantics> wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O), S(O)2N(Rs) or N(Rs)SO2, wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Lz<annotation encoding="application / x-tex">L_z< / annotation>< / semantics> is a (1-3C)alkylene; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- <semantics>4C<annotation encoding="application / x-tex">4C< / annotation>< / semantics>)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ર્જ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-4C)alkyl; and <semantics>Z5<annotation encoding="application / x-tex">Z_5< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, methyl, CH2F, CF2H or CF3; Xh, Xi and Xj are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; (59) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, OC(O), C(O)N(Rs), <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein <semantics>Rs<annotation encoding="application / x-tex">R^s< / annotation>< / semantics> and Rt are each independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: 91 denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rw)<annotation encoding="application / x-tex">OC(O)N(R^w)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z5<annotation encoding="application / x-tex">Z_5< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ર્જ denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy; Xh, Xi and Xi are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or C(O), C(O)O, OC(O), C(O)N(Rs), N(Rs)C(O), S(O)2N(Rs), N(Rs)SO2, wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, C(O), C(O)O, OC(O), C(O)N(Rw), <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)SO2<annotation encoding="application / x-tex">N(R^w)SO_2< / annotation>< / semantics>, wherein <semantics>Rw<annotation encoding="application / x-tex">R^w< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ેર્ denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy; (61) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ર્જુ denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F or CF2H; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or C(O), C(O)O, OC(O), C(O)N(Rs), N(Rs)C(O), S(O)2N(Rs), N(Rs)SO2, wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, OC(O), C(O)N(Rw), <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)SO2<annotation encoding="application / x-tex">N(R^w)SO_2< / annotation>< / semantics>, wherein <semantics>Rw<annotation encoding="application / x-tex">R^w< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-4C)alkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ાર્જ denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xq<annotation encoding="application / x-tex">X_q< / annotation>< / semantics> are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1-2C)haloalkyl or (1-2C)haloalkoxy; Xh, Xi and Xi are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy; i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ליל denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C) alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ر denotes the point of attachment; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, methyl, CH2F, CF2H or CF3; R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy; (63) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: ליל denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: 101 <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: ેર્ denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, acetylenyl, CH2F, CF2H or CF3; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro or methyl; R14 is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3; (64) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are both <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein <semantics>Rx1<annotation encoding="application / x-tex">R^{x1}< / annotation>< / semantics> is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; Xc and Xd are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro or methyl; R14 is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3; (65) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> is <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein <semantics>Rx1<annotation encoding="application / x-tex">R^{x1}< / annotation>< / semantics> is selected from hydrogen or chloro; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (2-4C)alkynyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc is selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; and iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; Xf and Xg are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro or methyl; R14 is selected from hydrogen, halo, methyl, OCH3, CH2F, CF2H or CF3; (66) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, 107 bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs),<annotation encoding="application / x-tex">C(O)N(R^s),< / annotation>< / semantics> <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and Wz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or 6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rw)<annotation encoding="application / x-tex">OC(O)N(R^w)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and Z₅ is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)haloalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; (67) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ર્જ denotes the point of attachment; Xa and Xb are independently selected from N or CRx1. wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs),<annotation encoding="application / x-tex">C(O)N(R^s),< / annotation>< / semantics> <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and Wz is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: ליל denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1 , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] - 1 - 1 N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)haloalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; (68) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ાર્જ denotes the point of attachment; Xa and Xb are independently selected from N or CRx1. wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs),<annotation encoding="application / x-tex">C(O)N(R^s),< / annotation>< / semantics> <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Lz is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- <semantics>4C<annotation encoding="application / x-tex">4C< / annotation>< / semantics>)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y5 is absent or O, N(Rw), C(O), C(O)O, OC(O), <semantics>C(O)N(Rw)<annotation encoding="application / x-tex">C(O)N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rw)<annotation encoding="application / x-tex">OC(O)N(R^w)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z5<annotation encoding="application / x-tex">Z_5< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; (69) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: رُ denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Lz is absent or a (1-3C)alkylene; and Wz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, C(O)Rxa, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ליל denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1- 4C)alkyl or cyclopropyl; (70) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ેર્ denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x_1}< / annotation>< / semantics> wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Lz<annotation encoding="application / x-tex">L_z< / annotation>< / semantics> is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- 4C)alkoxy, [Image disponible dans le document PDF, Image available in the PDF document] COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry 120 and Rz are each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl; (71) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), or S(O)2N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), wherein Rs is selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl; or Z³ is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is a (1-3C)alkylene; and Wz is halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, cyano, hydroxy, (1- 2C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics> COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; Xc and Xd are independently selected from N, CH, CF, CCI or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, <semantics>N(Rw)<annotation encoding="application / x-tex">N(R^w)< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics>, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-2C)alkyl; and <semantics>Z5<annotation encoding="application / x-tex">Z_5< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 8C)cycloalkyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1- 2C)alkyl; (72) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ેર્ denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, acetylenyl, CH₂F or CF₂H; R9 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or C(O), C(O)O, OC(O), C(O)N(Rs), N(Rs)C(O), S(O)2N(Rs), N(Rs)SO2, wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, OC(O), C(O)N(Rw), <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, <semantics>N(Rw)SO2<annotation encoding="application / x-tex">N(R^w)SO_2< / annotation>< / semantics>, wherein <semantics>Rw<annotation encoding="application / x-tex">R^w< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; (73) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano, nitro or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; Xc and Xd are independently selected from N, CH, CF, CCI or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)₂N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; (74) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ાર્જ denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are both <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein <semantics>Rx1<annotation encoding="application / x-tex">R^{x1}< / annotation>< / semantics> is selected from hydrogen, fluoro, chloro, bromo or methyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; Xc and Xd are independently selected from N, CH, CF, CCI or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; (75) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ેર્ denotes the point of attachment; Xb is CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo or methyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: ેર્ denotes the point of attachment; Xc is selected from N, CH, CF, CCI or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z₅ is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3- 6C)cycloalkenyl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; (76) R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xb is CRx1, wherein Rx1 is selected from hydrogen or chloro; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O), C(O)O, C(O)N(Rs) or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (2-4C)alkynyl, 5- or 6- membered heteroaryl or 5- or 6-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or (1-2C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc is selected from N, CH, CF, CCI or CCH3; R11 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1- 4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, 5 or 6 memebered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen or (1-2C)alkyl; <semantics>(77)<annotation encoding="application / x-tex">(77)< / annotation>< / semantics> R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1. wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> İS hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; and wherein each aryl, 5- or 6-membered heteroaryl or 4- to 7- membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1- 2C)haloalkyl, amino, cyano or hydroxy; (78) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ેર્ denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more (1-2C)alkyl groups; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is aryl, 5- or 6-membered heteroaryl, 4- to 7-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; (79) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ેર્ denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are independently selected from N or <semantics>CRx1<annotation encoding="application / x-tex">CR^{x1}< / annotation>< / semantics>, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH₂F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, SO, SO2, C(O), C(O)O, OC(O), <semantics>C(O)N(Rs),<annotation encoding="application / x-tex">C(O)N(R^s),< / annotation>< / semantics> <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, N(Rs)SO2, wherein Rs and Rt are each independently selected from hydrogen or (1- 4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, heteroaryl or 4 to 11- membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1- 4C)alkyl, (3-6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, cyano, hydroxy, (1- <semantics>4C<annotation encoding="application / x-tex">4C< / annotation>< / semantics>)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; (80) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O), or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl; or Z³ is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is a (1-3C)alkylene; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, cyano, hydroxy, (1- 2C) alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-2C)alkyl; (81) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa is CH or N; Xb is selected from CH, CCI, CF, CBr or CCH3; R9 is selected from chloro or cyano; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2), S, C(O), C(O)O, C(O)N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>), N(R<semantics>s<annotation encoding="application / x-tex">^{s}< / annotation>< / semantics>)C(O), or S(O)2N(Rs), wherein Rs is selected from hydrogen or (1-4C)alkyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3- 6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-3C)alkylene; and Wz is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano, hydroxy, (1-2C)alkoxy, C(O)Rxa, <semantics>COORxa<annotation encoding="application / x-tex">COOR^{xa}< / annotation>< / semantics>, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1-2C)alkyl; (82) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: ર્જ denotes the point of attachment; Xa is CH or N; Xb is selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from chloro or cyano; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0 or 1), <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics> or <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, wherein <semantics>Rs<annotation encoding="application / x-tex">R^s< / annotation>< / semantics> is selected from hydrogen or methyl; and <semantics>Z3<annotation encoding="application / x-tex">Z_3< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, aryl, (3- 6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from OXO, (1-3C)alkyl, cyclopropyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or methyl; or <semantics>Z3<annotation encoding="application / x-tex">Z^3< / annotation>< / semantics> is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is a (1-3C)alkylene; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, cyano, hydroxy, (1- 2C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, COORxa, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or methyl; (83) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa is CH or N; Xb is selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from chloro or cyano; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics> (where <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0 or 1), <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics> or <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, wherein <semantics>Rs<annotation encoding="application / x-tex">R^s< / annotation>< / semantics> is selected from hydrogen or methyl; and Z3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-3C)alkyl, cyclopropyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or methyl; (84) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa is CH or N; Xb is selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from chloro or cyano; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C) alkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y3 is absent or C(O)N(Rs), wherein Rs is selected from hydrogen or methyl; and Z3 is (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, cyano, hydroxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or methyl; (85) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> is CH or N; Xb is selected from CH, CCI, CF, CBr or CCH3; R9 is selected from chloro or cyano; R10 is selected from a (3-6C)cycloalkyl, a 5- or 6- membered heteroaryl or a 4 to 9-membered heterocyclyl; wherein said (3-6C)cycloalkyl, 5- or 6- membered heteroaryl or 4 to 9-membered heterocyclyl is optionally further substituted by one or more substituent groups independently selected from (1- 2C)alkyl, halo, (1-2C)haloalkyl, cyano, hydroxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or methyl; (86) R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> is CH or N; Xb is selected from CH, CCl, CF, CBr or CCH3; R9 is selected from chloro or cyano; R10 is selected from a 5- or 6-membered heteroaryl or a 4 to 8-membered heterocyclyl; wherein said 5- or 6- membered heteroaryl or 4 to 8-membered heterocyclyl is optionally further substituted by one or more substituent groups independently (1-4C)alkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano or hydroxy; (87) R3 is a compound of Formula A as defined in any one of paragraphs 54 to 86 above; (88) R3 is a compound of Formula B as defined in any one of paragraphs 54 to 76 above; (89) R3 is a compound of Formula C as defined in any one of paragraphs 54 to 65 above.

[0055] Suitably, a heteroaryl is a 5- or 6-membered heteroaryl ring comprising one, two or three heteroatoms selected from N, O or S.

[0056] Suitably, a heterocyclyl group is a 4-, 5- or 6-membered heterocyclyl ring comprising one, two or three heteroatoms selected from N, O or S. Most suitably, a heterocyclyl group is a 5-, 6- or 7-membered ring comprising one, two or three heteroatoms selected from N, O or S [e.g. morpholinyl (e.g. 4-morpholinyl), pyridinyl, piperazinyl, homopiperazinyl or pyrrolidinonyl].

[0057] Suitably an aryl group is phenyl.

[0058] Suitably, <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in any one of paragraphs (1) to 9) above. Most suitably, <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in paragraph (9) above.

[0059] Suitably, <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in any one of paragraphs (10) to (14) above. Most suitably, <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in paragraph (14) above.

[0060] Suitably, R1 is as defined in any one of paragraphs (15) to (31) above. Most suitably, R1 is as defined in paragraph (31) above.

[0061] Suitably, R2 is as defined in any one of paragraphs (32) to (53) above. Most suitably, R2 is as defined in any one of paragraphs (49) or (53) above.

[0062] Most suitably, R3 is as defined in any one of paragraphs (54) to (86) above. Most suitably R3 is as defined in paragraph (86) above.

[0063] In a particular group of compounds of the invention, X2 is CH, i.e. the compounds have the structural formula la (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula la wherein each of <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>, <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>, <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> and <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics> are as defined hereinabove.

[0064] In an embodiment of the compounds of Formula la: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in any one of paragraphs (1) to (9) above; R1 is as defined in any one of paragraphs (15) to (31) above; R2 is as defined in any one of paragraphs (32) to (53) above; and R3 is as defined in any one of paragraphs (54) to (86) above.

[0065] In another embodiment of the compounds of Formula la: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in paragraph (9) above; R1 is as defined in any one of paragraphs (28) to (31) above; R2 is as defined in any one of paragraphs (49) to (53) above; and R3 is as defined in paragraph (86) above.

[0066] In a particular group of compounds of the invention, <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> and <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> are CH, i.e. the compounds have the structural formula lb (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula lb wherein each of R1, R2 and R3 are as defined hereinabove.

[0067] In an embodiment of the compounds of Formula lb: R1 is as defined in any one of paragraphs (15) to (31) above; R2 is as defined in any one of paragraphs (32) to (53) above; and R3 is as defined in any one of paragraphs (54) to (86) above.

[0068] In another embodiment of the compounds of Formula lb: R1 is as defined in any one of paragraphs (28) to (31) above; R2 is as defined in any one of paragraphs (49) to (53) above; and R3 is as defined in paragraph (86) above.

[0069] In a particular group of compounds of the invention, R2 is of the formula shown below, i.e. the compounds have the structural formula Ic (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula Ic wherein each of <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>, <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>, <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>, <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>, <semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics> and <semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics> are as defined hereinabove.

[0070] In an embodiment of the compounds of Formula Ic: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in any one of paragraphs (1) to (9) above; 146 <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in any one of paragraphs (10) to (14) above; R1 is as defined in any one of paragraphs (15) to (31) above; W1 and W2 are as defined in any one of paragraphs (32) to (51) above; and R3 is as defined in any one of paragraphs (54) to (86) above.

[0071] In another embodiment of the compounds of Formula Ic: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in paragraph (9) above; X2 is as defined in paragraph (14) above; R1 is as defined in any one of paragraphs (28) to (31) above; W1 and W2 are as defined in paragraph (51) above; and R3 is as defined in paragraph (86) above.

[0072] In a particular group of compounds of the invention, <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> and <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> are CH and <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is of the formula shown below, i.e. the compounds have the structural formula Id (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula Id wherein each of R1, R3, W1 and W2 are as defined hereinabove

[0073] In an embodiment of the compounds of Formula Id: R1 is as defined in any one of paragraphs (15) to (31) above; W1 and W2 are as defined in any one of paragraphs (32) to (51) above; and R3 is as defined in any one of paragraphs (54) to (86) above.

[0074] In another embodiment of the compounds of Formula Id: R1 is as defined in any one of paragraphs (28) to (31) above; W1 and W2 are as defined in paragraph (51) above; and R3 is as defined in paragraph (86) above.

[0075] In a particular group of compounds of the invention, X1 and X2 are CH, R1 is methyl and R2 is of the formula shown below, i.e. the compounds have the structural formula le (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula le wherein each of R3, W1 and W2 are as defined hereinabove.

[0076] In an embodiment of the compounds of Formula le: W1 and W2 are as defined in any one of paragraphs (32) to (51) above; and R3 is as defined in any one of paragraphs (54) to (86) above.

[0077] In another embodiment of the compounds of Formula le: W¹ and W² are as defined in paragraph (51) above; and R3 is as defined in paragraph (86) above.

[0078] In a particular group of compounds of the invention, <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> and <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> are CH and <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is of the formula shown below, i.e. the compounds have the structural formula If (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula If wherein each of R1, R3 and R100 are as defined hereinabove.

[0079] In an embodiment of the compounds of Formula If: R1 is as defined in any one of paragraphs (15) to (31) above; R3 is as defined in any one of paragraphs (54) to (86) above; and R100 is as defined in any one of paragraphs (39) to (41), or (45) to (50) above.

[0080] In another embodiment of the compounds of Formula If: R1 is as defined in any one of paragraphs (28) to (31) above; R3 is as defined in paragraph (86) above; and R100 is -C(O)ORab, wherein Rab is selected from (1-2C)alkyl.

[0081] In a particular group of compounds of the invention, X1 and X2 are CH and R2 is of the formula shown below, i.e. the compounds have the structural formula lg (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula Ig wherein each of R1, R3, R101, R102 and ring A are as defined hereinabove.

[0082] In an embodiment of the compounds of Formula lg: R1 is as defined in any one of paragraphs (15) to (31) above; R3 is as defined in any one of paragraphs (54) to (86) above; and R101, R102 and ring A are as defined in any one of paragraphs (39) to (41), or (43) to (50) above.

[0083] In another embodiment of the compounds of Formula lg: R1 is as defined in any one of paragraphs (28) to (31) above; R3 is as defined in paragraph (86) above; and R101, R102 and ring A are as defined in paragraphs (49) or (50) above.

[0084] In a particular group of compounds of the invention, the compounds have the structural formula Ih (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula Ih wherein each of <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>, <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>, <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics>, <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics>, <semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>, <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>, <semantics>R9<annotation encoding="application / x-tex">R^9< / annotation>< / semantics> and <semantics>R10<annotation encoding="application / x-tex">R^{10}< / annotation>< / semantics> are as defined hereinabove.

[0085] In an embodiment of the compounds of Formula Ih: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in any one of paragraphs (1) to (9) above; <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in any one of paragraphs (10) to (14) above; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are as defined in any one of paragraphs (54) to (86) above; R1 is as defined in any one of paragraphs (15) to (31) above; R2 is as defined in any one of paragraphs (32) to (53) above; R9 is as defined in any one of paragraphs (54) to (86) above; and R10 is as defined in any one of paragraphs (54) to (86) above.

[0086] In another embodiment of the compounds of Formula Ih: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in paragraph (9) above; X2 is as defined in paragraph (14) above; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are as defined in paragraph (83) above; R1 is as defined in any one of paragraphs (28) to (31) above; R2 is as defined in any one of paragraphs (51) to (53) above; R9 is as defined in paragraph (86) above; and R10 is as defined in paragraph (86) above.

[0087] In a particular group of compounds of the invention, the compounds have the structural formula Ij (a sub-definition of Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof: [Image disponible dans le document PDF, Image available in the PDF document] Formula Ij wherein each of X1, X2, Xa, Xb, R1, R6, R7, R8, R9 and R10 are as defined hereinabove.

[0088] In an embodiment of the compounds of Formula Ij: <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is as defined in any one of paragraphs (1) to (9) above; <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in any one of paragraphs (10) to (14) above; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are as defined in any one of paragraphs (54) to (86) above; R1 is as defined in any one of paragraphs (15) to (31) above; R6, R7 and R8 are each as defined in any one of paragraphs (50) to (51) above; R9 is as defined in any one of paragraphs (54) to (86) above; and R10 is as defined in any one of paragraphs (54) to (86) above.

[0089] In another embodiment of the compounds of Formula Ij: X1 is as defined in paragraph (9) above; <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is as defined in paragraph (14) above; <semantics>Xa<annotation encoding="application / x-tex">X_a< / annotation>< / semantics> and <semantics>Xb<annotation encoding="application / x-tex">X_b< / annotation>< / semantics> are as defined in paragraph (86) above; R1 is as defined in any one of paragraphs (28) to (31) above; R6 is OH; R7 and R8 are CH3; R9 is as defined in paragraph (86) above; and R10 is as defined in paragraph (86) above.

[0090] Particular compounds of the present invention include any of the compounds exemplified in the present application, or a pharmaceutically acceptable salt or solvate thereof, and, in particular, any of the following: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 6-methyl-pyridine-3-carbonitrile; 6-chloro-5-cyano-4-[(1,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2- carboxylic acid; [Image disponible dans le document PDF, Image available in the PDF document] ylbutyl]benzimidazol-5-yl]amino]pyridine-2-carboxamide; 6-chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid; 6-chloro-5-cyano-N-methyl-4-[(1-methyl-2-oxo-3H-benzimidazol-5- yl)amino]pyridine-2-carboxamide; 6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]-N-methyl-pyridine-2-carboxamide; Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1,5-a]pyrimidine-5-carboxylate; 2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-butanoate; 2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; 2-chloro-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile; 5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3R)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one; [Image disponible dans le document PDF, Image available in the PDF document] benzimidazol-2-one; Ethyl 7-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1,5-a]pyrimidine-5-carboxylate; 4-chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile; 5-[(2,3-dichloro-4-pyridyl)amino]-3-[(3R)-3-hydroxybutyl]-1-methyl-benzimidazol-2- one; Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrazolo[1,5-a]pyrimidine-5-carboxylate; Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Ethyl 6-chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate; 6-Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid; Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methyl-propanoate; Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)amino]-3-methyl-2-oxo-benzimidazol- 1-yl]-2-methyl-butanoate; 6-Chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]-N-methyl-pyridine-2-carboxamide; Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate; Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate; Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate; Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate; Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate; 6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1,3-dimethyl-2-oxo-benzimidazol- 5-yl)amino]pyridine-2-carboxamide; Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1,5-a]pyrimidine-5-carboxylate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-hydroxy-butanoate; 2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-methoxy-butanoate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-ethoxy-butanoate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate; methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]- 2-(cyclopropylmethoxy)butanoate; 2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; 2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile; 2-chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate; Methyl (2R)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate; N-[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-1- methyl-propyl]acetamide; 5-Chloro-N-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide; 5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3- methyl-butyl)-1-methyl-benzimidazol-2-one; 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-1H-pyrazole-4-carboxylate; ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-3,5-dimethyl-1H-pyrazole-4- carboxylate; 5-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3,5-dihydroxy- 3-methylpentyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylpentyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(dimethylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 1-(5-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4- carboxamide; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-4- methoxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-(5-chloro-4-((3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 1-(5-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 5-((5-chloro-2-(1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 6-(3,5-dimethyl-1H-pyrazol-1-yl)-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-bromo-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; [Image disponible dans le document PDF, Image available in the PDF document] 5-((5-chloro-2-(1H-indazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(1H-indazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 2-chloro-4-((3-(2-(1-hydroxycyclobutyl)ethyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-(2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-2-oxo-3-(3-oxopentyl)-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-((2-methyltetrahydrofuran-3-yl)methyl)-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; tert-butyl 2-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-1-yl)methyl)azetidine-1-carboxylate; 5-((6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-(2-hydroxypropan-2-yl)-3- methyloxazolidin-2-one; 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 5-((5-chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(isopropylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; [Image disponible dans le document PDF, Image available in the PDF document] methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2- one; 5-((6-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3- methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3- methyloxazolidin-2-one; 5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one; 5-((6-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3- methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one; 5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-morpholinopyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2S,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2R,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(methylthio)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 2-chloro-4-((3-((5-ethyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 4-chloro-6-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidine-5-carbonitrile; 2-chloro-4-((3-((5-ethyl-3-methyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylpentyl)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 3-(3-hydroxy-3-methylbutyl)-1-methyl-5-((2,5,6-trichloropyrimidin-4-yl)amino)-1,3- dihy...

Claims

<pat:ClaimStatement>CLAIMS< / pat:ClaimStatement> <pat:Claims com:id="claims"> <pat:Claim com:id="CLM-00001"> <pat:ClaimNumber>1< / pat:ClaimNumber> <pat:ClaimText>1. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (I) wherein: X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R1 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: L is absent or (1-2C)alkylene; and Z is (1-6C)alkyl, (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy, NRgRh or ORg; wherein Rg and Rh are each independently selected from hydrogen or (1-2C)alkyl; R2 is selected from: (i) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CR4R5 or C(O), wherein R4 and R5 are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, nitro, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRjRk, wherein Rj and Rk are independently selected from hydrogen or (1-2C)alkyl; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano or hydroxy; <semantics>W2<annotation encoding="application / x-tex">W_2< / annotation>< / semantics> is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, <semantics>C(O)R1<annotation encoding="application / x-tex">C(O)R^1< / annotation>< / semantics>, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl or (1- 2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4- 6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, <semantics>C(O)R∘<annotation encoding="application / x-tex">C(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)OR∘<annotation encoding="application / x-tex">C(O)OR^{\circ}< / annotation>< / semantics>, <semantics>OC(O)R∘<annotation encoding="application / x-tex">OC(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)N(R∘)Rp<annotation encoding="application / x-tex">C(O)N(R^{\circ})R^{p}< / annotation>< / semantics>, <semantics>NR∘C(O)Rp<annotation encoding="application / x-tex">NR^{\circ}C(O)R^{p}< / annotation>< / semantics>, wherein R° and R° are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano or hydroxyl; or (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 4 to 6 membered cycloalkyl or heterocyclyl ring, optionally substituted with one or more substituent groups selected from (1-2C)alkyl, halo, hydroxy, cyano or (1-2C)alkoxy; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl, -C(O)-CH3 or - C(O)ORab, wherein Rab is (1-4C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, cyclopropyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy, -C(O)ORac, -NRacRad, phenyl or a 5-membered heteroaryl, wherein Rac and Rad are independently selected from hydrogen or (1- 2C)alkyl; and R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or O, N(Rs)(CRsRt)q1, S, SO, SO2, C(O), C(O)O, <semantics>OC(O)<annotation encoding="application / x-tex">OC(O)< / annotation>< / semantics>, <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>N(Rs)C(O)N(Rt)<annotation encoding="application / x-tex">N(R^s)C(O)N(R^t)< / annotation>< / semantics>, <semantics>N(Rs)C(O)O<annotation encoding="application / x-tex">N(R^s)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rs)<annotation encoding="application / x-tex">OC(O)N(R^s)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein q1 is 0, 1 or 2, wherein Rs and Rt are each independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2- 4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3- 6C)cycloalkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)hydoxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: LZ is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and <semantics>WZ<annotation encoding="application / x-tex">W_Z< / annotation>< / semantics> is aryl, heteroaryl, 4- to 7-membered heterocyclyl, 3- to 6-membered carbocycyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1- 4C)alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, <semantics>C(O)ORxa<annotation encoding="application / x-tex">C(O)OR^{xa}< / annotation>< / semantics>, <semantics>C(O)NRxaRxb<annotation encoding="application / x-tex">C(O)NR^{xa}R^{xb}< / annotation>< / semantics> or <semantics>NRxaRxb<annotation encoding="application / x-tex">NR^{xa}R^{xb}< / annotation>< / semantics>, wherein Rxa and Rxb are each independently selected from hydrogen or (1- 4C)alkyl; and wherein each aryl, heteroaryl, 4- to 7- membered heterocyclyl or 3- to 6-membered carbocycyl is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano or hydroxy; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCl, C- CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2- 4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, OC(O), C(O)N(Rw), <semantics>N(Rw)C(O)<annotation encoding="application / x-tex">N(R^w)C(O)< / annotation>< / semantics>, <semantics>N(Rw)C(O)N(Rx)<annotation encoding="application / x-tex">N(R^w)C(O)N(R^x)< / annotation>< / semantics>, <semantics>N(Rw)C(O)O<annotation encoding="application / x-tex">N(R^w)C(O)O< / annotation>< / semantics>, <semantics>OC(O)N(Rw)<annotation encoding="application / x-tex">OC(O)N(R^w)< / annotation>< / semantics>, S(O)2N(Rw), N(Rw)SO2, wherein Rw and Rx are each independently selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3- 8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)hydroxyalkyl, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics> are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, (1-2C)alkyl, (1- 2C)haloalkyl or (1-2C)haloalkoxy; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy; with the proviso that: (i) when R3 is a group of Formula B, no more than two of Xc, Xd and Xe are nitrogen; and (ii) when <semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics> is a group of Formula C, no more than three of <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics>, <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics>, <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are nitrogen. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00002"> <pat:ClaimNumber>2< / pat:ClaimNumber> <pat:ClaimText>2. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00003"> <pat:ClaimNumber>3< / pat:ClaimNumber> <pat:ClaimText>3. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claims 1 or 2, wherein X2 is selected from N or CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00004"> <pat:ClaimNumber>4< / pat:ClaimNumber> <pat:ClaimText>4. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 3, wherein X1 is CH and X2 is CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00005"> <pat:ClaimNumber>5< / pat:ClaimNumber> <pat:ClaimText>5. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 4, wherein R1 is selected from (1-6C)alkyl or (3- 6C)cycloalkyl; wherein each (1-6C)alkyl or (3-6C)cycloalkyl is optionally further substituted by one or more substituent groups independently selected from oxo, (1-2C)alkyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, amino, (1-2C)aminoalkyl, cyano, hydroxy or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00006"> <pat:ClaimNumber>6< / pat:ClaimNumber> <pat:ClaimText>6. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 5, wherein R1 is (1-4C)alkyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00007"> <pat:ClaimNumber>7< / pat:ClaimNumber> <pat:ClaimText>7. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 6, wherein R2 is selected from: (i) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CR4R5 or C(O), wherein R4 and R5 are independently selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; or R4 and R5 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6- membered heterocyclic ring, which is optionally substituted by one or more substituents selected from methyl, fluoro, chloro, OCH3, amino, cyano or hydroxy; <semantics>W2<annotation encoding="application / x-tex">W_2< / annotation>< / semantics> is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, C(O), C(O)O, OC(O), C(O)N(Rn) or N(Rn)C(O, wherein Rn is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano, nitro or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 and R102 are each independently selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, (1-2C)alkoxy, CH2F, CF2H, CF3, -C(O)ORac or- NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00008"> <pat:ClaimNumber>8< / pat:ClaimNumber> <pat:ClaimText>8. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 6, wherein R2 is selected from: (i) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4 or C(O), wherein R4 is selected from hydrogen, (1-2C)alkyl, fluoro, hydroxy, cyano, (1-2C)alkoxy, CH2F, CF2H or amino; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)OCH3, C(O)N(H)CH3, CR6R7R8 or NR1Rm, wherein R1 and Rm are independently selected from hydrogen or (1-2C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, (1-2C)alkoxy, CH2F or CF2H; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y2<annotation encoding="application / x-tex">Y_2< / annotation>< / semantics> is absent or selected from O, C(O)O, C(O)N(Rn) or N(Rn)C(O), wherein Rn is selected from hydrogen or (1-2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4-6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, (1-2C)alkoxy, (1-2C)alkylamino, amino, cyano or hydroxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, NRqRr, phenyl or a 5- membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atoms to which they are attached, they form a 4-6 membered carbocyclic ring or a 4-6 membered heterocyclic ring; or (ii) a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: ેર્ denotes the point of attachment; ring A is a 5-membered cycloalkyl or heterocyclyl ring; W3 is selected from NR100 or CR101R102, wherein R100 is selected from hydrogen, (1-2C)alkyl or -C(O)ORab, wherein Rab is (1-2C)alkyl, R101 is selected from hydrogen or methyl and R102 is selected from (1-2C)alkyl, hydroxy, (1-2C)alkoxy, C(O)ORac or -NRacRad, and wherein Rac and Rad are independently selected from hydrogen or (1-2C)alkyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00009"> <pat:ClaimNumber>9< / pat:ClaimNumber> <pat:ClaimText>9. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 8, wherein R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics>, S, C(O), C(O)O, <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics>, <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics> or <semantics>N(Rs)SO2<annotation encoding="application / x-tex">N(R^s)SO_2< / annotation>< / semantics>, wherein q1 is 0, 1 or 2, wherein Rs and Rt are independently selected from hydrogen or (1- 4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3- 6C)cycloalkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1- 4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-3C)alkylene; and WZ is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, <semantics>C(O)ORxa<annotation encoding="application / x-tex">C(O)OR^{xa}< / annotation>< / semantics>, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or S(O)2N(Rw), wherein Rw is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or (3- 6C)cycloalkyl; iii) a group of Formula C shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula C wherein: denotes the point of attachment; R12 is selected from fluoro, chloro, bromo, (1-2C)alkyl, (1- 2C)alkoxy, cyano, nitro, (2-4C)alkynyl, CH2F, CF2H or CF3; <semantics>Xf<annotation encoding="application / x-tex">X_f< / annotation>< / semantics> and <semantics>Xg<annotation encoding="application / x-tex">X_g< / annotation>< / semantics> are independently selected from N or CR13, wherein R13 is selected from hydrogen, fluoro, chloro, methyl, CH2F, CF2H or CF3; <semantics>Xh<annotation encoding="application / x-tex">X_h< / annotation>< / semantics>, <semantics>Xi<annotation encoding="application / x-tex">X_i< / annotation>< / semantics> and <semantics>Xj<annotation encoding="application / x-tex">X_j< / annotation>< / semantics> are independently selected from N or CR14, wherein R14 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1- 2C)haloalkyl or (1-2C)haloalkoxy. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00010"> <pat:ClaimNumber>10< / pat:ClaimNumber> <pat:ClaimText>10. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 8, wherein R3 is selected from: i) a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa and Xb are independently selected from N or CRx1. wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R9 is selected from hydrogen, fluoro, chloro, bromo, (1- 2C)alkyl, (1-2C)alkoxy, cyano, nitro, acetylenyl, CH2F, CF2H or CF3; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CRsRt)q1<annotation encoding="application / x-tex">N(R^s)(CR^sR^t)_{q_1}< / annotation>< / semantics>, S, C(O), C(O)O, <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, <semantics>N(Rs)C(O)<annotation encoding="application / x-tex">N(R^s)C(O)< / annotation>< / semantics> or <semantics>S(O)2N(Rs)<annotation encoding="application / x-tex">S(O)_2N(R^s)< / annotation>< / semantics>, wherein <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0, 1 or 2, wherein Rs and Rt are independently selected from hydrogen or (1-4C)alkyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-4C)alkyl, (3-6C)cycloalkyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; and / or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>LZ<annotation encoding="application / x-tex">L_Z< / annotation>< / semantics> is absent or a (1-5C)alkylene optionally substituted by one or more substituents selected from (1-2C)alkyl or oxo; and WZ is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1- 4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, <semantics>(1−4C)<annotation encoding="application / x-tex">(1-4C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, <semantics>C(O)ORxa<annotation encoding="application / x-tex">C(O)OR^{xa}< / annotation>< / semantics>, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or (1-4C)alkyl; ii) a group of Formula B shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula B wherein: denotes the point of attachment; Xc, Xd and Xe are independently selected from N, CH, CF, CCI, C-CN or CCH3; R11 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-4C)alkynyl or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y5<annotation encoding="application / x-tex">Y_5< / annotation>< / semantics> is absent or O, N(Rw), C(O), C(O)O, C(O)N(Rw) or <semantics>S(O)2N(Rw)<annotation encoding="application / x-tex">S(O)_2N(R^w)< / annotation>< / semantics>, wherein <semantics>Rw<annotation encoding="application / x-tex">R^w< / annotation>< / semantics> is selected from hydrogen or (1-4C)alkyl; and Z5 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; wherein Z5 is optionally further substituted by one or more substituent groups independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, carbamoyl, sulphamoyl, mercapto, NRyRz, ORy, wherein Ry and Rz are each independently selected from hydrogen, (1-4C)alkyl or cyclopropyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00011"> <pat:ClaimNumber>11< / pat:ClaimNumber> <pat:ClaimText>11. A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 1 to 10, wherein R3 is a group of Formula A shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula A wherein: denotes the point of attachment; Xa is CH or N; Xb is selected from N or CRx1, wherein Rx1 is selected from hydrogen, fluoro, chloro, bromo, methyl, OCH3, cyano or acetylenyl; R9 is selected from chloro or cyano; R10 is selected from hydrogen, halo, (1-4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: <semantics>Y3<annotation encoding="application / x-tex">Y_3< / annotation>< / semantics> is absent or <semantics>N(Rs)(CH2)q1<annotation encoding="application / x-tex">N(R^s)(CH_2)_{q_1}< / annotation>< / semantics>, <semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>, <semantics>C(O)O<annotation encoding="application / x-tex">C(O)O< / annotation>< / semantics> or <semantics>C(O)N(Rs)<annotation encoding="application / x-tex">C(O)N(R^s)< / annotation>< / semantics>, wherein <semantics>q1<annotation encoding="application / x-tex">q_1< / annotation>< / semantics> is 0 or 1, wherein <semantics>Rs<annotation encoding="application / x-tex">R^s< / annotation>< / semantics> is selected from hydrogen or methyl; and Z3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 9-membered heterocyclyl; wherein Z3 is optionally further substituted by one or more substituent groups independently selected from oxo, (1-3C)alkyl, cyclopropyl, halo, (1-2C)haloalkyl, (1- 2C)haloalkoxy, amino, cyano, hydroxy, amido, carboxy, C(O)NRuRv, NRuRv or ORu, wherein Ru and Rv are each independently selected from hydrogen or methyl; or Z3 is optionally further substituted by a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: LZ is absent or a (1-3C)alkylene; and WZ is phenyl, 5- or 6-membered heteroaryl, 6-membered heterocyclyl, halo, (1- 2C)haloalkyl, (1-2C)haloalkoxy, cyano, hydroxy, <semantics>(1−2C)<annotation encoding="application / x-tex">(1-2C)< / annotation>< / semantics>alkoxy, <semantics>C(O)Rxa<annotation encoding="application / x-tex">C(O)R^{xa}< / annotation>< / semantics>, <semantics>C(O)ORxa<annotation encoding="application / x-tex">C(O)OR^{xa}< / annotation>< / semantics>, C(O)NRxaRxb or NRxaRxb, wherein Rxa and Rxb are each independently selected from hydrogen or methyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00012"> <pat:ClaimNumber>12< / pat:ClaimNumber> <pat:ClaimText>12. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from one of the following: [Image disponible dans le document PDF, Image available in the PDF document] 2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6- methyl-pyridine-3-carbonitrile; 6-chloro-5-cyano-4-[(1,3-dimethyl-2-oxo-benzimidazol-5-yl)amino]pyridine-2-carboxylic acid; 6-chloro-5-cyano-N-methyl-4-[[1-methyl-2-oxo-3-[(3S)-3-pyrazol-1-ylbutyl]benzimidazol- 5-yl]amino]pyridine-2-carboxamide; 6-chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylic acid; 6-chloro-5-cyano-N-methyl-4-[(1-methyl-2-oxo-3H-benzimidazol-5-yl)amino]pyridine-2- carboxamide; 6-chloro-5-cyano-4-[[3-(3-hydroxy-3-methyl-butyl)-2-oxo-1-(tetrahydropyran-4- ylmethyl)benzimidazol-5-yl]amino]-N-methyl-pyridine-2-carboxamide; Ethyl 7-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1,5-a]pyrimidine-5-carboxylate; 2-chloro-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2- methyl-butanoate; 2-bromo-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; 2-chloro-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]-6-methyl- pyridine-3-carbonitrile; 5-[(2,5-dichloro-4-pyridyl)amino]-3-[(3R)-3-hydroxybutyl]-1-methyl-benzimidazol-2-one; 5-[(2,5-dichloropyrimidin-4-yl)amino]-3-(3-hydroxy-3-methyl-butyl)-1-methyl- benzimidazol-2-one; Ethyl 7-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyrazolo[1,5- alpyrimidine-5-carboxylate; 4-chloro-6-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrimidine-5-carbonitrile; 5-[(2,3-dichloro-4-pyridyl)amino]-3-[(3R)-3-hydroxybutyl]-1-methyl-benzimidazol-2-one; Ethyl 3-fluoro-7-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol- 5-yl)amino)pyrazolo[1,5-a]pyrimidine-5-carboxylate; Methyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Ethyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Isopropyl 6-chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylate; Ethyl 6-chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxylate; 6-Chloro-5-cyano-4-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo- benzimidazol-5-yl]amino]pyridine-2-carboxylic acid; Methyl 3-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-2- methyl-propanoate; Methyl 4-[6-[(5-chloro-2-methyl-pyrimidin-4-yl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]-2-methyl-butanoate; 6-Chloro-5-cyano-4-[[3-[(3R)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]- N-methyl-pyridine-2-carboxamide; Methyl 4-[6-[[2-chloro-3-cyano-6-(3-methyl-1,2,4-oxadiazol-5-yl)-4-pyridyl]amino]-3- methyl-2-oxo-benzimidazol-1-yl]-2-methyl-butanoate; Methyl (2S)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate; Methyl 4-[6-[[2-chloro-3-cyano-6-(methylcarbamoyl)-4-pyridyl]amino]-3-methyl-2-oxo- benzimidazol-1-yl]-2-methyl-butanoate; Methyl 4-[6-[[6-(but-3-ynylcarbamoyl)-2-chloro-3-cyano-4-pyridyl]amino]-3-methyl-2- oxo-benzimidazol-1-yl]-2-methyl-butanoate; Methyl 4-[6-[[2-chloro-3-cyano-6-(dimethylcarbamoyl)-4-pyridyl]amino]-3-methyl-2-oxo- benzimidazol-1-yl]-2-methyl-butanoate; 6-Chloro-5-cyano-N-[2-(dimethylamino)ethyl]-4-[(1,3-dimethyl-2-oxo-benzimidazol-5- yl)amino]pyridine-2-carboxamide; Ethyl 7-[[3-(4-methoxy-3-methyl-4-oxo-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyrazolo[1,5-a]pyrimidine-5-carboxylate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-2- hydroxy-butanoate; 2-Chloro-4-[[3-(2,3-dihydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-2- methoxy-butanoate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-2- ethoxy-butanoate; Methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]butanoate; methyl 4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-2- (cyclopropylmethoxy)butanoate; 2-chloro-4-[[3-(2-hydroxy-3-pyrazol-1-yl-propyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-3-carbonitrile; 2-chloro-4-[[3-(2-cyanobutyl)-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine-3- carbonitrile; 2-chloro-4-[[3-[(3S)-3-hydroxybutyl]-1-methyl-2-oxo-benzimidazol-5-yl]amino]pyridine- 3-carbonitrile; Methyl 2-[[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1- yl]methyl]cyclopentanecarboxylate; Methyl (2R)-2-amino-4-[6-[(2-chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo- benzimidazol-1-yl]butanoate; N-[3-[6-[(2-Chloro-3-cyano-4-pyridyl)amino]-3-methyl-2-oxo-benzimidazol-1-yl]-1- methyl-propyl]acetamide; 5-Chloro-N-ethyl-4-[[3-(3-hydroxy-3-methyl-butyl)-1-methyl-2-oxo-benzimidazol-5- yl]amino]pyridine-2-carboxamide; 5-[[5-Chloro-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-yl]amino]-3-(3-hydroxy-3-methyl- butyl)-1-methyl-benzimidazol-2-one; 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-1H-pyrazole-4-carboxylate; ethyl 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-3,5-dimethyl-1H-pyrazole-4-carboxylate; 5-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3,5-dihydroxy-3- methylpentyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylpentyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(dimethylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 1-(5-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-4- methoxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-(5-chloro-4-((3-(3,5-dihydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 1-(5-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 5-((5-chloro-2-(1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 6-(3,5-dimethyl-1H-pyrazol-1-yl)-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-bromo-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(5-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(1H-indazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(1H-indazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 2-chloro-4-((3-(2-(1-hydroxycyclobutyl)ethyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-(2-(methylsulfonyl)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-2-oxo-3-(3-oxopentyl)-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-((2-methyltetrahydrofuran-3-yl)methyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; tert-butyl 2-((6-((2-chloro-3-cyanopyridin-4-yl)amino)-3-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)methyl)azetidine-1-carboxylate; 5-((6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2-oxo- 2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-(2-hydroxypropan-2-yl)-3- methyloxazolidin-2-one; 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; 5-((5-chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(isopropylamino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(ethyl(methyl)amino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2-one; 5-((6-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyl-3-methyloxazolidin-2-one; 5-((6-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one; 5-((6-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-methyl-2- oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)-5-ethyloxazolidin-2-one; 5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-6-fluoro-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-morpholinopyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl- 1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2S,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2R,6R)-2-cyclopropyl-6-methylmorpholino)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(methylthio)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl- 1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 2-chloro-4-((3-((5-ethyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 4-chloro-6-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyrimidine-5-carbonitrile; 2-chloro-4-((3-((5-ethyl-3-methyl-2-oxooxazolidin-5-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((6-fluoro-3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylpentyl)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl- 1,3-dihydro-2H-benzo[d]imidazol-2-one; 3-(3-hydroxy-3-methylbutyl)-1-methyl-5-((2,5,6-trichloropyrimidin-4-yl)amino)-1,3- dihydro-2H-benzo[d]imidazol-2-one; (R)-6-chloro-5-cyano-4-((3-(3-methoxybutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)-N-methylpicolinamide; 4-((3-(3-acetamido-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)-6-chloro-5-cyano-N-methylpicolinamide; 5-((5,6-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro- 2H-benzo[d]imidazol-2-one; 2-chloro-4-((3-(((1S,2S)-2-ethyl-2-hydroxycyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(((1S,2S)-2-hydroxy-2-methylcyclopentyl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((5-chloro-2-(1-methyl-1H-pyrazol-3-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(1,3-dimethyl-1H-pyrazol-5-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2,4-dimethylthiazol-5-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(thiophen-2-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(1-methyl-1H-imidazol-2-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 2-chloro-4-((1-methyl-2-oxo-3-((4-(2,2,2-trifluoroethyl)morpholin-3-yl)methyl)-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(2-(dimethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; (S)-2-chloro-4-((3-((1-ethylpyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-2-oxo-3-((1-(2,2,2-trifluoroethyl)piperidin-2-yl)methyl)-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; (S)-2-chloro-4-((3-((1-(2-fluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; (S)-2-chloro-4-((3-((1-(2-hydroxyethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(((2R,4S)-4-fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-(ethylamino)butyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-hydroxy-3-methylhex-5-yn-1-yl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-hydroxy-4-methoxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-hydroxy-3-methylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-2-oxo-3-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-hydroxy-2,3-dimethylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(3-hydroxy-3,4-dimethylpentyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2-(trifluoromethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((3-chloro-2-fluoropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3- dihydro-2H-benzo[d]imidazol-2-one; 5-((2,3-dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro- 2H-benzo[d]imidazol-2-one; 5-((3-bromopyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H- benzo[d]imidazol-2-one; 5-((5-chloro-2-(trifluoromethyl)pyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl- 1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((3-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H- benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1- methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; (S)-5-((5-chloro-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; (S)-7-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)-5-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile; 2-chloro-4-((1-methyl-3-(2-(2-methyloxiran-2-yl)ethyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((3-(2-(3,5-dimethyl-2-oxooxazolidin-5-yl)ethyl)-1-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 2-chloro-4-((1-methyl-3-((5-methyl-2-oxooxazolidin-4-yl)methyl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)nicotinonitrile; (S)-5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1-methyl-3-((1- (2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1,3-bis(3-hydroxy-3-methylbutyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1,3-bis(3-hydroxy- 3-methylbutyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(2,2-difluoro-7-azaspiro[3.5]nonan-7-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-(5-chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)amino)pyridin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; (R)-2-chloro-4-((3-(3-hydroxybutyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5- yl)amino)nicotinonitrile; (S)-2-chloro-4-((3-((1-(2,2-difluoroethyl)pyrrolidin-2-yl)methyl)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile; 5-((5-chloro-2-(4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4,4-difluoro-3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3R,4S)-3,4-difluoropyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-((1R,5S)-8-azabicyclo[3.2.1]octan-8-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-((1R,5S)-3-azabicyclo[3.2.1]octan-3-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3aR,7aS)-octahydro-2H-isoindol-2-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3R,4S)-3,4-dimethylpyrrolidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy- 3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1,3-bis(3-hydroxy- 3-methylbutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 6-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)- 1,3-bis(3-hydroxy-3-methylbutyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; 5-((5-chloro-2-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-((1r,3r,5r,7r)-2-azaadamantan-2-yl)-5-chloropyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 4-chloro-6-((5-chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-4-yl)amino)-1,3-bis(3- hydroxy-3-methylbutyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-(methoxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3R,5S)-3,5-dimethylazepan-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-(3-phenylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((2-(4-((1H-pyrazol-1-yl)methyl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyridin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3R,5S)-3,5-dimethylpiperidine-1-carbonyl)pyridin-4-yl)amino)-3-(3- hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidine-1-carbonyl)pyridin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2- one; 5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1- (2-(dimethylamino)ethyl)-3-(3-hydroxy-3-methylbutyl)-1,3-dihydro-2H-benzo[d]imidazol- 2-one; 5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3- (3-hydroxy-3-methylbutyl)-1-(2-morpholinoethyl)-1,3-dihydro-2H-benzo[d]imidazol-2- one; ethyl (E)-4-(5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)but- 2-enoate; 5-((5-Chloro-2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)- 1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; 5-[[5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]pyrimidin-4-yl]amino]-1-(2- hydroxyethyl)-3-(3-hydroxy-3-methyl-butyl)benzimidazol-2-one; 5-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-1- (2,2-dimethoxyethyl)-3-(3-hydroxy-3-methylbutyl)-1,3-dihydro-2H-benzo[d]imidazol-2- one; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 5-((5-chloro-2-(2-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2- one; 5-((5-chloro-2-(1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridin-6-yl)pyrimidin-4- yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2- one; 5-((5-chloro-2-(3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; [Image disponible dans le document PDF, Image available in the PDF document] 5-((2-(4-(1H-pyrazol-1-yl)piperidin-1-yl)-5-chloropyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one; or 5-((5-chloro-2-(2-(hydroxymethyl)morpholino)pyrimidin-4-yl)amino)-3-(3-hydroxy-3- methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00013"> <pat:ClaimNumber>13< / pat:ClaimNumber> <pat:ClaimText>13. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or hydrate thereof, for use in therapy. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00014"> <pat:ClaimNumber>14< / pat:ClaimNumber> <pat:ClaimText>14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or excipient. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00015"> <pat:ClaimNumber>15< / pat:ClaimNumber> <pat:ClaimText>15. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 13, for use in the treatment of cancer. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00016"> <pat:ClaimNumber>16< / pat:ClaimNumber> <pat:ClaimText>16. A compound or a pharmaceutical composition for use according to claim 15, wherein said cancer is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC) or squamous cell carcinomas (SCC) of the head and neck, oesophagus, lung or ovary. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00017"> <pat:ClaimNumber>17< / pat:ClaimNumber> <pat:ClaimText>17. A use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt or hydrate thereof, or a pharmaceutical composition according to claim 14for the treatment of cancer in a subject in need of such treatment. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00018"> <pat:ClaimNumber>18< / pat:ClaimNumber> <pat:ClaimText>18. A use according to claim 17, wherein said cancer is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC) or squamous cell carcinomas (SCC) of the head and neck, oesophagus, lung or ovary. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00019"> <pat:ClaimNumber>19< / pat:ClaimNumber> <pat:ClaimText>19. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, as shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (II) wherein: X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano, or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; R1 is methyl; <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W₁ is selected from CR⁴R⁵, wherein R⁴ and R⁵ are hydrogen, W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)R1, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8, or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, or (1- 2C)haloalkoxy; R' is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy, or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> <semantics>N(Rn)SO2<annotation encoding="application / x-tex">N(R^n)SO_2< / annotation>< / semantics>, wherein <semantics>Rn<annotation encoding="application / x-tex">R^n< / annotation>< / semantics> is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and <semantics>Z2<annotation encoding="application / x-tex">Z_2< / annotation>< / semantics> is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl or a 4- 6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, <semantics>C(O)R∘<annotation encoding="application / x-tex">C(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)OR∘<annotation encoding="application / x-tex">C(O)OR^{\circ}< / annotation>< / semantics>, <semantics>OC(O)R∘<annotation encoding="application / x-tex">OC(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)N(R∘)Rp<annotation encoding="application / x-tex">C(O)N(R^{\circ})R^{p}< / annotation>< / semantics>, or <semantics>NR∘C(O)Rp<annotation encoding="application / x-tex">NR^{\circ}C(O)R^{p}< / annotation>< / semantics>, wherein R° and R° are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq ORq, -C(O)NRq, NRqRr, phenyl, or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, or hydroxyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00020"> <pat:ClaimNumber>20< / pat:ClaimNumber> <pat:ClaimText>20. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to claim 19, wherein X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano, or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00021"> <pat:ClaimNumber>21< / pat:ClaimNumber> <pat:ClaimText>21. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to claims 19 or 20, wherein X2 is selected from N or CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00022"> <pat:ClaimNumber>22< / pat:ClaimNumber> <pat:ClaimText>22. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 19 to 21, wherein <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is CH and <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00023"> <pat:ClaimNumber>23< / pat:ClaimNumber> <pat:ClaimText>23. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 19 to 22, wherein R2 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; and R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00024"> <pat:ClaimNumber>24< / pat:ClaimNumber> <pat:ClaimText>24. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, as shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (II) wherein: X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano, or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; R1 is methyl; <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4, wherein R4 is selected from hydrogen, (1- 2C)alkyl, fluoro, hydroxy, cyano, or (1-2C)alkoxy; W2 is CR6R7R8, wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl, or pyrazole, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00025"> <pat:ClaimNumber>25< / pat:ClaimNumber> <pat:ClaimText>25. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to claim 24, wherein X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano, or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00026"> <pat:ClaimNumber>26< / pat:ClaimNumber> <pat:ClaimText>26. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to claims 24 or 25, wherein X2 is selected from N or CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00027"> <pat:ClaimNumber>27< / pat:ClaimNumber> <pat:ClaimText>27. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 24 to 26, wherein X1 is CH and X2 is CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00028"> <pat:ClaimNumber>28< / pat:ClaimNumber> <pat:ClaimText>28. A compound of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 23 to 27, wherein R2 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; and R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00029"> <pat:ClaimNumber>29< / pat:ClaimNumber> <pat:ClaimText>29. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, as shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (IV) wherein: X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano, or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; R1 is methyl; <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is CR4R5, wherein R4 and R5 are hydrogen; W2 is selected from cyano, a 5- or 6-membered heteroaryl, phenyl, C(O)R1, SO2RI, C(O)OCH3, C(O)N(H)CH3, CR6R7R8, or NRIRm, wherein RI and Rm are independently selected from hydrogen or (1-4C)alkyl, and wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, amino, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, or (1- 2C)haloalkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, cyano, nitro, (1-2C)alkoxy, (1-2C)haloalkyl, (1- 2C)haloalkoxy, or a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y2 is absent or selected from O, N(Rn), S, SO, SO2, C(O), <semantics>C(O)O,OC(O),C(O)N(Rn),N(Rn)C(O),S(O)2N(Rn),or<annotation encoding="application / x-tex">C(O)O, OC(O), C(O)N(R^n), N(R^n)C(O), S(O)_2N(R^n), or< / annotation>< / semantics> N(Rn)SO2, wherein Rn is selected from hydrogen or (1- 2C)alkyl; L2 is absent or (1-2C)alkylene; and Z2 is hydrogen, (1-6C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, phenyl, (3-6C)cycloalkyl, 5-6 membered heteroaryl, or a 4- 6-membered heterocyclyl; wherein Z2 is optionally substituted by one or more substituents selected from (1- 4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)alkoxy, (1-4C)alkylamino, amino, cyano, nitro, hydroxy, <semantics>C(O)R∘<annotation encoding="application / x-tex">C(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)OR∘<annotation encoding="application / x-tex">C(O)OR^{\circ}< / annotation>< / semantics>, <semantics>OC(O)R∘<annotation encoding="application / x-tex">OC(O)R^{\circ}< / annotation>< / semantics>, <semantics>C(O)N(R∘)Rp<annotation encoding="application / x-tex">C(O)N(R^{\circ})R^{p}< / annotation>< / semantics>, or <semantics>NR∘C(O)Rp<annotation encoding="application / x-tex">NR^{\circ}C(O)R^{p}< / annotation>< / semantics>, wherein R° and R° are independently selected from hydrogen or (1-4C)alkyl; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl, or a 5-membered heteroaryl, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl; and or R6 and R7 can be linked such that, together with the carbon atom to which they are attached, they form a 3-6-membered carbocyclic ring or a 3-6-membered heterocyclic ring, which is optionally substituted by one or more substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1- 2C)alkylamino, amino, cyano, or hydroxyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00030"> <pat:ClaimNumber>30< / pat:ClaimNumber> <pat:ClaimText>30. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to claim 29, wherein X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano, or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00031"> <pat:ClaimNumber>31< / pat:ClaimNumber> <pat:ClaimText>31. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to claims 29 or 30, wherein X2 is selected from N or CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00032"> <pat:ClaimNumber>32< / pat:ClaimNumber> <pat:ClaimText>32. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 29 to 31, wherein <semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics> is CH and <semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics> is CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00033"> <pat:ClaimNumber>33< / pat:ClaimNumber> <pat:ClaimText>33. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 29 to 32, wherein R2 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; and R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00034"> <pat:ClaimNumber>34< / pat:ClaimNumber> <pat:ClaimText>34. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, as shown below: [Image disponible dans le document PDF, Image available in the PDF document] Formula (IV) wherein: X1 is selected from N or CRa, wherein Ra is selected from hydrogen, (1-2C)alkyl, halogen, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (2-4C)alkenyl, (2-4C)alkynyl, nitro, cyano, or NRbRc, wherein Rb and Rc are independently selected from hydrogen or (1-2C)alkyl; X2 is selected from N or CRd, wherein Rd is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, bromo, hydroxy, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; R1 is methyl; <semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics> is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: denotes the point of attachment; W1 is selected from CHR4, wherein R4 is selected from hydrogen, (1- 2C)alkyl, fluoro, hydroxy, cyano, or (1-2C)alkoxy; <semantics>W2<annotation encoding="application / x-tex">W_2< / annotation>< / semantics> is <semantics>CR6R7R8<annotation encoding="application / x-tex">CR^6R^7R^8< / annotation>< / semantics> R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy; and R8 is selected from (1-2C)alkyl, -C(O)ORq, ORq, -C(O)NRq, NRqRr, phenyl, or pyrazole, wherein Rq and Rr are independently selected from hydrogen or (1-2C)alkyl. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00035"> <pat:ClaimNumber>35< / pat:ClaimNumber> <pat:ClaimText>35. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to claim 34, wherein X1 is selected from N or CRa, wherein Ra is selected from hydrogen, methyl, fluoro, chloro, hydroxy, OCH3, CH2F, CHF2, CF3, OCF3, acetylenyl, cyano, or NH2. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00036"> <pat:ClaimNumber>36< / pat:ClaimNumber> <pat:ClaimText>36. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to claims 34 or 35, wherein X2 is selected from N or CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00037"> <pat:ClaimNumber>37< / pat:ClaimNumber> <pat:ClaimText>37. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 34 to 36, wherein X1 is CH and X2 is CH. < / pat:ClaimText> < / pat:Claim> <pat:Claim com:id="CLM-00038"> <pat:ClaimNumber>38< / pat:ClaimNumber> <pat:ClaimText>38. A compound of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 34 to 37, wherein R2 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: R6 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, amino, cyano, or (1-2C)alkoxy; and R7 is selected from hydrogen, (1-2C)alkyl, fluoro, chloro, hydroxy, cyano, (1-2C)alkoxy, (1-2C)haloalkyl, or (1-2C)haloalkoxy. < / pat:ClaimText> < / pat:Claim> < / pat:Claims>